Waters Corporation outperformed Q2 revenue estimates, driven by strong sales to the pharmaceutical sector, and subsequently raised its full-year guidance. The company's recent announcement to acquire BD’s Biosciences and Diagnostics Solutions portfolio signals strategic expansion. Waters’ favorable performance reflects resilience in life science instrument demand amid industry headwinds, reinforcing confidence in its growth trajectory.